Abstract |
Breast and colon tumor response to emoxyl, a nitroxyl derivative of daunomycin, was detected using human tumor heterotransplantation under the renal capsule of immunocompetent mice. The substitution of adriamycin by emoxyl in the combined therapy led to enhanced therapeutic efficacy. The evidence of enhanced response of breast tumors to emoxyl obtained during the histologic examination of xenografts is in good agreement with measurements of tumor fragment weight. It is suggested to use a quantitative kinetic index kappa calculated by the method of equivalent exponents for objective evaluation of tumor response to the drugs.
|
Authors | N P Konovalova, R F Diatchkovskaya, L Kh Ganieva, L M Volkova, I M Lapshin, Rudakov BYa, Shaposhnikov YuG, A B Shapiro |
Journal | Neoplasma
(Neoplasma)
Vol. 38
Issue 3
Pg. 275-84
( 1991)
ISSN: 0028-2685 [Print] Slovakia |
PMID | 1857448
(Publication Type: Journal Article)
|
Chemical References |
- aclacinomycins
- Aclarubicin
- Doxorubicin
- Emoxyl
- Cyclophosphamide
- Fluorouracil
- Daunorubicin
|
Topics |
- Aclarubicin
(analogs & derivatives, pharmacology)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Colonic Neoplasms
(drug therapy)
- Cyclophosphamide
(pharmacology)
- Daunorubicin
(analogs & derivatives, pharmacology, therapeutic use)
- Dose-Response Relationship, Drug
- Doxorubicin
(analogs & derivatives, therapeutic use)
- Evaluation Studies as Topic
- Fluorouracil
(therapeutic use)
- Humans
- Mice
- Neoplasm Transplantation
- Subrenal Capsule Assay
|